<DOC>
	<DOC>NCT00250276</DOC>
	<brief_summary>Human papillomavirus infection has clearly been recognized as the cause of cervical cancer. Indeed, the infection of the cervix by certain oncogenic types of HPV, if not cleared , can lead over time to cervical cancer in women . This study will compare the immune response induced by different lots of the HPV-16/18 L1/AS04 vaccine, following adjustments to the manufacturing process.</brief_summary>
	<brief_title>Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>A female subject between, and including, 18 and 25 years of age at the time of the first vaccination. Written informed consent obtained from the subject prior to enrolment. Subject must have a negative urine pregnancy test. Healthy subject before entering the study entry as established by medical history and physical examination. Subject must be of nonchildbearing potential. pregnant or breastfeeding subject. previous vaccination against human papillomavirus (HPV). Known acute or chronic, clinically significant neurologic, hepatic or renal functional abnormality. History of chronic condition(s) requiring treatment such as cancer, chronic hepatic or kidney disease(s), diabetes or autoimmune disease.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>